HighTide Therapeutics, Inc. 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：2511） 截至二零二五年十二月三十一日止年度的 全年業績公告以及所得款項用途變更 君聖泰醫藥（「本公司」，連同其子公司統稱「本集團」）董事（「董事」）會（「董事 會」）欣然公佈本集團截至二零二五年十二月三十一日止年度（「報告期間」）的經審 核綜合全年業績。該等全年業績已由董事會審核委員會（「審核委員會」）審閱。 於本公告內，「我們」及「我們的」均指本公司，如文義另有所指，則指本集團。 本公告所載若干金額及百分比數字已約整或已四捨五入至小數點後一位或兩位數 （如適用）。任何表格、圖表或其他地方所示總額與本公告所列數額總和如有任何 差異乃因四捨五入所致。 1 管理層討論及分析 概覽 我們是一家新型生物醫藥公司，專注於研究和開發心腎代謝系統疾病(CKM)領域 的突破性治療方案，為全球患者帶來綜合獲益。 CK ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 HighTide Therapeutics, Inc. 1 管理層討論及分析 概覽 我們是一家新型生物醫藥公司，專注於研究和開發心腎代謝系統疾病(CKM)領域 的突破性治療方案，為全球患者帶來綜合獲益。 CKM相關疾病領域存在重大的未滿足臨床需求，給患者和其家庭帶來了沉重負 擔。這些疾病往往具有共通的致病機制，從而導致多種代謝性共病的發生，這不 僅加劇了疾病管理的複雜性，還使得患者預後不佳。我們正在開發能解決疾病核 心問題並降低患者共病風險的突破性治療方案，旨在為患者帶來全面健康獲益。 我們的核心產品HTD1801是一款全球首創新分子實體(NME)，旨在解決CKM 相關疾病。HTD1801是一款口服抗炎及代謝調節劑，具有獨特雙機制，通過激 活AMPK及抑制NLRP3炎症小體發揮其生物學活性。激活AMPK可調控能量穩 態，抑制NLRP3炎症小體可緩解系統性炎症，兩種機制協同互補，有效治療代 謝性慢病及心血 ...

HighTide Therapeutics, Inc. （於開曼群島註冊成立的有限公司） （股份代號：2511） 董事會會議召開日期通告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 君聖泰醫藥（「本公司」）董事會（「董事會」）謹此宣佈，董事會會議將於二零二六 年三月二十七日（星期五）舉行，藉以（其中包括）審議及批准本公司及其附屬公司 截至二零二五年十二月三十一日止年度之經審核全年業績及其發佈，以及處理其 他事項。 承董事會命 君聖泰醫藥 執行董事兼行政總裁 劉利平博士 香港，二零二六年三月十三日 於本公告日期，董事會成員由執行董事劉利平博士及於萌女士；非執行董事朱迅 博士、馬立雄先生及江峰先生；以及獨立非執行董事譚擘先生、李靖博士及孔德 偉先生組成。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 本公告由君聖泰醫藥（「本公司」，連同其附屬公司統稱為「本集團」）自願發佈，以 告知本公司股東及潛在投資者有關本集團的最新業務發展。 本公司董事會（「董事會」）宣佈，中國國家藥品監督管理局(NMPA)已受理 HTD1801用於治療2型糖尿病(T2DM)的新藥上市申請(NDA)。這是君聖泰醫藥提 交的首個新藥上市申請，也是公司邁向產品商業化的重要里程碑。 HTD1801已完成3項針對T2DM適應症的多中心、隨機、雙盲、對照的III期臨床 研究，均達主要終點和多項次要終點，在血糖、血脂、炎症、腎功能等多個心腎 代謝關鍵維度呈現出一致的改善趨勢，充分展現了其一藥多效、綜合獲益的臨床 價值。 香港聯合交易所有限公司證券上市規則第18A.05條規定的警示聲明：本公司無法 保證HTD1801最終會成功上市。本公司股東及潛在投資者於買賣本公司股份時務 請審慎行事。 HighTide Therapeutics, Inc. ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 君圣泰医药（於開曼群島註冊成立的有限公司） 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02511 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.0001 USD | | 100,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.0001 USD | | 100,000 | 本月底法定/註冊股本總額： ...

Core Insights - The meeting held by Junshengtai Pharmaceutical focused on the company's strategic layout in the cardiovascular, kidney, and metabolic (CKM) disease sector and the interpretation of various clinical research data [1] - The appointment of Dr. Filip Surmont as the new Chief Medical Officer is significant, given his extensive experience in the field and the potential of the innovative drug HTD1801 to redefine treatment paradigms in CKM diseases [1][4] Market Potential - CKM diseases are evolving from a clinical concept to a major health challenge, with a significant market opportunity driven by the interconnected nature of these diseases [3] - The global market for major metabolic diseases was approximately $160 billion in 2022 and is projected to reach $458 billion by 2032, with a compound annual growth rate (CAGR) of 11.1% [3] Industry Trends - Traditional pharmaceutical companies often rely on a broad product portfolio targeting individual diseases, while companies like Junshengtai are focusing on developing multi-functional drugs that address multiple issues simultaneously [4] - The industry is shifting from single-target drugs to combination therapies and now to single drugs with multiple targets, aligning with global treatment trends [4] Product Innovation - HTD1801 is a globally innovative oral drug designed to address CKM diseases through a unique dual mechanism that improves metabolic disorders and controls chronic inflammation [6] - The drug combines two natural components, berberine and ursodeoxycholic acid, to form a new molecular entity that targets the root causes of CKM diseases [6] Clinical Efficacy - Clinical trials have demonstrated HTD1801's effectiveness in lowering HbA1c levels by 1.3% in patients with Type 2 Diabetes Mellitus (T2DM) after 24 weeks of treatment, showcasing its long-term blood sugar control capabilities [10] - In patients with mild kidney impairment, HTD1801 showed a significant improvement in estimated glomerular filtration rate (eGFR) by +3.08 mL/min/1.73m², indicating potential disease-modifying effects [11] - HTD1801 also outperformed the traditional drug Dapagliflozin in reducing low-density lipoprotein cholesterol levels, suggesting comprehensive benefits for CKM patients [11] Strategic Positioning - HTD1801 is positioned as a cornerstone therapy in the CKM field, with analysts predicting it will establish a clear differentiation and unique value proposition in a competitive treatment landscape [12] - Junshengtai's approach reflects a broader shift in the pharmaceutical industry towards patient-centered care and holistic treatment strategies [14]

Core Insights - The company is leading a new era in comprehensive treatment for cardiovascular, kidney, and metabolic diseases (CKM) through its "one drug, multiple effects" strategy [1][2] Group 1: Clinical Developments - The company presented breakthrough data from its oral drug HTD1801 in a pivotal Phase III clinical trial (HARMONY study) for type 2 diabetes, showing superiority over the mainstream drug Dapagliflozin in reducing glycated hemoglobin and improving various cardiovascular metabolic indicators [1] - The company also shared data and development potential for chronic kidney disease (CKD) and the Phase IIb clinical results for metabolic-associated fatty liver disease (MASH) [1] Group 2: Leadership and Strategy - The new Chief Medical Officer (CMO) Dr. Filip Surmont made his official debut at the meeting, bringing over 30 years of global experience in cardiovascular, metabolic, and kidney diseases, including 18 years in senior medical leadership roles at multinational pharmaceutical companies like Pfizer and AstraZeneca [1] - Dr. Surmont's experience in leading medical affairs and driving successful clinical development in key global markets is expected to accelerate the company's CKM pipeline's research and implementation worldwide [1]

Group 1 - The company announced the completion of a global multicenter Phase IIb clinical study for HTD1801 in patients with Metabolic Associated Steatotic Liver Disease (MASH) [1] - The CENTRICITY trial (NCT05623189) involved 218 patients and aimed to evaluate the efficacy and safety of HTD1801 compared to a placebo in MASH patients with Type 2 Diabetes Mellitus (T2DM) or prediabetes [1] - Preliminary analysis showed that 48% of patients in the placebo group achieved a reduction of ≥2 points in the Non-Alcoholic Fatty Liver Disease Activity Score (NAS) without fibrosis worsening, significantly higher than previous studies where placebo effects were typically below 20% [1] Group 2 - Following a review by a third-party organization, issues related to patient medication management and adherence were identified, which may have significantly impacted trial results [2] - After excluding these confounding factors, the placebo effect was found to decrease significantly, and HTD1801 showed a trend of therapeutic improvement in several liver histological indicators [2] - The company plans to reassess the clinical development strategy for HTD1801 in MASH based on the overall data, review findings, and post-hoc analysis conclusions, and will communicate with the FDA for further evaluation of the development plan [2]

Group 1 - The core finding of the global multicenter Phase IIb clinical trial CENTRICITY (NCT05623189) for HTD1801 in patients with Metabolic Associated Steatotic Liver Disease (MASH) indicates that 48% of patients in the placebo group achieved a reduction of ≥2 points in the Non-Alcoholic Fatty Liver Disease Activity Score (NAS) without fibrosis worsening, which is significantly higher than the typical placebo effect observed in similar studies [1] - A meta-analysis published in 2025 covering 127 clinical trials for 78 different investigational drugs indicated that the placebo effect in similar trials usually does not exceed 20% [1] Group 2 - Following a review by a third-party organization, issues related to patient medication management and adherence during the trial were identified, which may have significantly impacted the trial results [2] - After excluding abnormal interference factors such as non-compliance with medication protocols, the placebo effect was found to decrease significantly, showing HTD1801 exhibited a trend of therapeutic improvement in several liver histological indicators [2] - The long-term safety and tolerability of HTD1801 in this study were consistent with previous clinical research results, and the company plans to further evaluate the clinical development strategy for HTD1801 in MASH indications based on the overall data and findings from this study [2]

Group 1 - The core viewpoint of the news is that Junsheng Tai Pharmaceutical-B (02511.HK) has completed a global multicenter Phase IIb clinical study of HTD1801 in patients with Metabolic Associated Steatotic Liver Disease (MASH) [1] - The CENTRICITY trial (NCT05623189) involved 218 patients and aimed to evaluate the efficacy and safety of HTD1801 compared to a placebo in MASH patients with type 2 diabetes (T2DM) or prediabetes [1] - Preliminary analysis showed that 48% of patients in the placebo group achieved a reduction of ≥2 points in the Non-Alcoholic Fatty Liver Disease Activity Score (NAS) without fibrosis worsening, significantly higher than previous studies where placebo effects were typically below 20% [1] Group 2 - Following a review by a third-party organization, issues were identified in the management of concomitant medications and patient compliance during the trial, which may have significantly impacted the results [2] - After excluding abnormal interference factors such as non-compliant medication use, the placebo effect was found to decrease significantly, indicating a treatment improvement trend for HTD1801 in several liver histological indicators [2] - The post-hoc analysis results suggest that the study was influenced by multiple execution and quality management factors, while HTD1801 demonstrated long-term safety and tolerability consistent with previous clinical research findings [2]